Avid Bioservices Inc (CDMO)

[Thurly]

The control arm results of this trial are rock-solid in line with historical norms.

3-12-2012 Roth Q&A, STEVE KING (with our results inserted):
...you have a disease in which you have a less than 10% Tumor Resp. Rate (our trial: 7.9%), PFS of less than 3 months. (our trial: 3 months.), MOS less than 6 months. (our trial: less than 6 months)...
http://tinyurl.com/7837qym

AA or PIII?

Peregrine says they expect to run a PIII trial. From the PR:

These results give us a high level of confidence as we begin planning for Phase III development in this indication,” said Joseph Shan, vice president, clinical and regulatory affairs at Peregrine.

and

These data will be instrumental in planning Phase III development in NSCLC // said Steven W. King, president and chief executive officer of Peregrine.